Trifecta Stocks Portfolio Manager Bryan Ashenberg, CFA offers viewers his take on Merck and why he believes investors should take note. The pharmaceutical space is white hot now with Novartis and GlaxoSmithKline swapping over $20 billion in assets and Pfizer making a run at AstraZeneca. Ashenberg highlights why he believes upcoming catalysts should continue to push the shares higher as investors re-engage with this under-appreciated pharmaceutical company.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
